Piramal Life Sciences Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2016. For the period, the company’s net sales/income from operation was INR 6.5 million against INR 7.6 million a year ago. Loss from operations before other income, finance costs and exceptional items of INR 1.3 million against INR 11.7 million a year ago. Loss from ordinary activities before tax INR 0.6 million compared with INR 1.12 million a year ago. Net loss for the period was INR 0.6 million compared with INR 1.12 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.0 against INR 0.4 a year ago.